secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2026-08-13T11:30:16+00:00
Accession:  0001493152-26-037574
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus discontinues Decoy20 enrollment, no active clinical programs; Q2 net loss $1.8M
--------------------------------------------------------------------------------

- Q2 2026 net loss $1.8M vs $5.2M in Q2 2025; six-month loss $4.3M vs $9.8M; EPS loss $0.02 vs $9.09.
- Decoy20 enrollment discontinued; no participants remain in any clinical study; no active clinical development programs.
- June 17, 2026 private placement: 20M shares at $0.60/share, $12.0M gross proceeds; cash+investments $11.6M at June 30.
- R&D expenses down 83% to $0.4M (Q2) and $0.9M (six months); G&A down 37% to $1.4M (Q2).
- Annual meeting elected David Natan, Tim Ruan, Dr. Johnny Fox Arrowsmith as Class II directors; approved 2026 equity plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226037574/0001493152-26-037574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226037574/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer